Main Therapeutic Uses

Spasmorest is primarily used to manage functional disturbances of the gastrointestinal tract. It is designed to alleviate symptoms associated with smooth muscle spasms in the digestive system.

Gastrointestinal Conditions

The medication is commonly indicated for the relief of symptoms related to several digestive disorders, including:

• Irritable Bowel Syndrome (IBS): Helps manage abdominal pain, cramping, and discomfort associated with bowel sensitivity.
• Gastrointestinal Spasms: Relieves acute spasms of the stomach or intestines.
• Biliary Colic: May be used as an adjunctive treatment for discomfort arising from the biliary tract.
• Diverticulitis: Assists in reducing the localized cramping often associated with inflammation of the colonic wall.

Benefits and Mechanism of Action

Spasmorest functions as an antispasmodic agent. Its primary benefit is the relaxation of the smooth muscles within the gut wall, which helps to restore normal motility and reduce painful contractions.

Key Benefits

• Pain Reduction: By targeting the source of the spasm, the medication helps reduce the intensity of abdominal pain.
• Restoration of Comfort: It assists in decreasing the bloating and cramping that often follow meals or stress-induced digestive episodes.
• Targeted Action: The medication acts specifically on the musculature of the digestive tract to provide relief without significantly affecting other bodily systems.

Who can and cannot use Spasmorest? (Mebeverine Hydrochloride)

Official regulatory information strictly defines the populations permitted, restricted, or prohibited from using Spasmorest (Mebeverine Hydrochloride).

Absolute Contraindications

Spasmorest is contraindicated and must not be used by individuals with known hypersensitivity to mebeverine hydrochloride or any of its excipients. Use is also prohibited for patients with specific rare hereditary problems of sugar intolerance, such as galactose intolerance or glucose-galactose malabsorption, as these excipients are present in certain formulations.

Age- and Reproductive-Based Restrictions

Population Group	Regulatory Status
Children/Adolescents (Under 18)	Not recommended for tablet formulations due to insufficient safety and efficacy data.
Pregnant Women	Not recommended due to limited data.
Breastfeeding Women	Should not be used.
Adults & Older Adults	Permitted under standard labeled conditions.

Conditional Use and Caution

While no dosage adjustment is deemed necessary for patients with renal or hepatic impairment, the medicine should be used with caution in cases of advanced liver disease or advanced renal disease.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Spasmorest (Dicycloverine) based primarily on its anticholinergic activity, resulting in both pharmacodynamic and pharmacokinetic concerns with specific co-administered agents. The following interactions are formally documented in government regulatory sources.

---

Pharmacodynamic and Absorption Interactions

Interaction Type	Interacting Agent Categories	Official Interaction Outcome
Additive Anticholinergic Effects	Other Anticholinergic Agents, Narcotic Analgesics	May increase certain actions or side effects, leading to additive effects.
Pharmacodynamic Antagonism	Antiglaucoma Agents, Gastrointestinal Motility Drugs	May antagonize the intended therapeutic effects of these agents.
Altered Absorption	Antacids, Slow-Dissolving Digoxin Forms	Antacids may interfere with Spasmorest absorption; may result in increased serum concentrations of slow-dissolving Digoxin forms.

---

Administration Constraints

The most significant interaction constraint relates to timing separation: the simultaneous use of Antacids and Spasmorest should be avoided because antacids may interfere with the drug's absorption. No combinations are formally classified as contraindicated due to a drug-drug interaction risk itself. Regulatory data does not explicitly document any specific CYP-mediated metabolic or transporter-based interactions.

Antagonism of Muscarinic Acetylcholine Receptors

Dicycloverine's primary mechanism involves acting as a competitive antagonist at peripheral muscarinic acetylcholine receptors ( mAChR) in the gut. This molecular block attenuates the cholinergic signaling from the parasympathetic nervous system, which normally drives intestinal contractions. This action initiates a cascade that reduces the signal-dependent mobilization of intracellular calcium ( Ca^2+), a required step for muscle shortening.

---

Direct Smooth Muscle Relaxation (Musculotropic Effect)

The drug exhibits a secondary musculotropic mechanism that complements its primary action by directly influencing the smooth muscle fiber itself, independent of the acetylcholine receptor. This targeted pathway modulation functionally stabilizes the muscle cell and results in relaxation, providing a non-cholinergic component to the resultant spasmolytic effect.

---

Consequence of Non-Selective Pathway Modulation

As the drug engages its mechanism across M1, M2, and M3 receptor subtypes, the functional effects are not confined to the gut; the mechanism inherently results in a reduction in glandular secretions and modulates other systems where autonomic tone is regulated by cholinergic pathways.

The administration of Spasmorest, which contains the active ingredient Dicycloverine, is conducted via the oral route (as tablets, capsules, or syrup) and as an intramuscular (IM) injection. The oral route represents the primary method of use, with the injectable solution reserved strictly for short-term, necessary situations when oral administration is not feasible.

The standardized adult oral regimen is initiated at 20 mg taken four times a day (QID). After one full week of treatment at the initial dose, the regimen may be escalated to 40 mg QID, establishing the maximum total daily dosage at 160 mg. The frequency for all approved routes remains four times daily. The IM dose ranges from 10 mg to 20 mg per administration. Strict procedural conditions apply to the IM route: administration must be IM only, and the syringe must be aspirated before injection to avoid the intravascular route. This use is severely restricted and is not recommended for administration beyond 1 or 2 days. Oral therapy is expected to replace the IM route as soon as possible.

Regarding population-specific use, Dicycloverine is contraindicated in infants younger than 6 months. The overall duration of use is also constrained; if an inadequate effect is observed after a 2-week trial, particularly if the tolerated dose remains below 80 mg per day, the medicine is to be discontinued.

Research Evidence / Overview of Studies for Spasmorest

Evidence for Symptomatic Treatment of Irritable Bowel Syndrome (IBS)

Research for this medicine, which includes the active substance mebeverine, has been applied in studies examining outcomes related to physical discomfort in people diagnosed with Irritable Bowel Syndrome (IBS). The primary evidence base consists of multiple Randomized Controlled Trials (RCTs), along with subsequent Systematic Reviews and Meta-analyses, where researchers examined conditions characterized by fluctuating or episodic manifestations where symptoms may vary in intensity.

Studies were conducted during periods of increased symptom activity and research explored whether the medicine was associated with changes in patient-reported outcomes describing perceived discomfort. Trials have evaluated endpoints such as abdominal pain measurements, overall global symptom assessment, and monitoring of bowel habits (e.g., stool consistency). Findings describe patterns observed in the studies where some trials reported that the active substance was observed to relate to changes in abdominal pain measurements.

However, the findings were mixed across the assembled clinical trials. Systematic reviews analyzing the body of evidence have noted inconsistent results when assessing overall global improvement compared to a placebo. The evidence quality varies across studies, and the level of certainty in the overall body of research is currently classed as Moderate, indicating that conclusions are often based on trials with methodological differences.

---

Research Base for Gastrointestinal Smooth Muscle Spasm

The evidence for the active ingredient dicycloverine (dicyclomine) was studied for its role in conditions characterized by smooth muscle spasm and cramping. Research explored short-term symptom changes in populations, primarily adult patients with diagnosed IBS. Studies monitored outcomes including measuring abdominal pain intensity, the frequency of cramping, and overall patient-reported improvement.

The available evidence for dicycloverine has been characterized in regulatory reviews as being of very low quality, with methodological limitations and a high risk of bias often noted. Research provides insight into short-term changes, but there is a paucity of modern, well-designed clinical trials to fully assess the drug’s role in symptom management.

---

What Remains Uncertain About the Research for Spasmorest

The current evidence landscape highlights key limitations that should be noted. The evidence quality varies across studies, leading to mixed findings in meta-analyses, which suggests that certainty remains low in some areas of symptom management. A significant research gap is the limited data available for long-term outcomes. Additionally, due to the modest sample sizes and short follow-up durations in older trials, the findings describe group patterns but do not provide specific individual predictions. The assembled research contributes to the broader evidence landscape but has not fully established the drug's role in all potential patient scenarios, leaving some areas of understanding incomplete.

Key Studies & References The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review

Common questions about Spasmorest (FAQ)

Q: Is Spasmorest intended for short-term use, or can it be taken long-term?

A: Official instructions require discontinuation if an adequate effect is not observed after a two-week trial. Furthermore, official safety information for the maximum recommended doses is generally not available for use lasting longer than two weeks. The constraints related to the two-week trial and lack of long-term data suggest the medicine is primarily intended for short-term symptom relief.

Q: Will taking Spasmorest always cause some level of drowsiness or sedation?

A: Official information indicates that drowsiness is a reported side effect, along with somnolence and lightheadedness. This effect does not occur in everyone who takes the drug; official product information, based on clinical trials, reports that drowsiness was experienced by 9% of patients.

Q: How common is the dry mouth side effect reported with Spasmorest?

A: Dry mouth is frequently noted in official product information as a side effect. Official product information notes that dry mouth was frequently reported in clinical studies, with approximately 33% of patients experiencing this effect.

Q: Can Spasmorest be taken with common anti-depressant or anti-anxiety medications?

A: Regulatory documents caution that the medicine can have additive effects when combined with other drugs that cause drowsiness or have anticholinergic activity. This potential interaction profile includes some medications used to treat anxiety or depression, such as certain benzodiazepines and tricyclic antidepressants. Official guidance emphasizes informing a healthcare provider about all current medications.

Q: Why is Spasmorest generally unsuitable for older adults or seniors?

A: Official labeling advises caution for older adults because they may be more sensitive to certain anticholinergic side effects. These potential effects include confusion, fast heartbeat, constipation, and difficulty with urination. For this population, official guidance describes that dose selection should be approached cautiously.

Q: Is Spasmorest available in a generic version, and is it comparable to the brand-name product?

A: The medicine's active component, Dicyclomine, is widely available as a generic formulation, distinguishing it from the Spasmorest brand-name product. Generic availability is a standard practice for many medicines.

Q: Is Spasmorest known to be unsuitable for people who have glaucoma?

A: Regulatory documents state that the medicine is strictly contraindicated (should not be used) in people with angle-closure glaucoma. This restriction is based on the potential for the drug to affect this specific condition.

Q: Are there different formulations of Spasmorest (e.g., immediate-release vs. extended-release)?

A: The medicine is available as an oral tablet, capsule, or syrup, in addition to an injectable solution. The standard regimen for the oral forms is four times a day. This dosing frequency aligns with the characteristics of an immediate-release formulation.

Q: Does Spasmorest affect the ability to sweat, and is this a concern in hot weather?

A: The official safety information indicates that this medicine may reduce the body’s ability to sweat. This potential reduction in cooling increases the risk for fever or heat stroke. Caution related to heat is advised in the official safety information.

Q: Why are antispasmodics like Spasmorest sometimes not recommended for long-standing digestive issues?

A: Official instructions advise discontinuing the medicine if an adequate effect is not achieved within a two-week trial. Furthermore, the lack of extensive safety data for prolonged use at higher doses reinforces the medicine’s regulatory constraint to short-term use.

Q: Does Spasmorest affect the central nervous system (CNS) like some other spasm drugs?

A: Yes. Regulatory safety information reports central nervous system (CNS) effects that include confusion, disorientation, and hallucinations. Psychosis is also noted as a reported effect in sensitive individuals.

Q: How quickly does Spasmorest usually take to start working after a dose?

A: Official product information indicates that the drug is rapidly absorbed after being taken by mouth. It reaches its highest concentration in the bloodstream approximately 60 to 90 minutes after an oral dose. This timeline, documented in official product information, indicates the window when the onset of effect typically begins.

Q: What is the expected duration of the anti-spasm effect after taking Spasmorest?

A: The elimination half-life of the medicine, which is the time required for half the dose to leave the body, is approximately 5 to 10 hours. This half-life is consistent with the standard four times per day dosing schedule described in regulatory documents.

Q: Can Spasmorest cause dizziness or lightheadedness, and what is the rate of occurrence?

A: Dizziness and lightheadedness are reported in the official adverse reaction data. Official product information reports dizziness in 29% of patients and lightheadedness in 11% of patients, classifying both as common effects.

Q: Is there a risk of dependency or addiction associated with Spasmorest?

A: Regulatory-aligned patient information states that while rare, the medicine has been associated with abnormal drug-seeking behavior, which is sometimes referred to as addiction.

Q: Can Spasmorest cause withdrawal symptoms if the medicine is stopped abruptly?

A: Withdrawal symptoms may rarely occur if the medicine is stopped suddenly after regular, long-term use. These reported symptoms can include dizziness, sweating, and vomiting.

Q: Does Spasmorest interact with over-the-counter pain medications, such as ibuprofen or acetaminophen?

A: Regulatory-aligned interaction information indicates that common over-the-counter pain relievers, specifically Acetaminophen and Acetylsalicylic acid (Aspirin), may decrease how quickly the body excretes this medicine. This effect could potentially result in higher levels of the medicine in the bloodstream.

Q: What happens if Spasmorest is taken with common cold and flu medicines?

A: Official warnings advise checking the labels of cold and flu products, as these often contain ingredients (such as antihistamines) that can cause drowsiness or a fast heartbeat. Combining these with Spasmorest may result in additive effects, increasing the risk of such reactions.

Q: Is there an interaction between Spasmorest and alcohol consumption?

A: Regulatory-aligned information advises caution regarding alcohol consumption. Alcohol may increase the severity of certain side effects, such as drowsiness and dizziness. Official guidance advises limiting or using alcohol cautiously.

Q: Are there any specific supplements or herbal products that should be avoided with Spasmorest?

A: Official guidance includes informing healthcare providers about all products being used. This includes prescription and nonprescription drugs, as well as herbal and dietary supplements.

Q: Is it generally safe to use Spasmorest while driving or operating machinery?

A: Official warnings state that the medicine may cause drowsiness or blurred vision. Due to this potential effect on mental alertness, patients should avoid driving or operating machinery.

Q: Is it possible for Spasmorest to cause problems with urination or urinary retention?

A: Difficulty with urination (urinary hesitancy) and urinary retention are documented adverse effects of the medicine.

Q: Can Spasmorest affect a person's vision or cause blurred eyesight?

A: Official safety information reports blurred vision as a common side effect, noting a frequency of 27% in clinical studies. Other visual effects such as dilated pupils (mydriasis) are also explicitly listed in the official safety information.

Q: Does Spasmorest cause constipation, and how common is this side effect?

A: Constipation is listed in the official documents as a documented adverse effect related to the gastrointestinal system.

Q: Is Spasmorest known to cause heart-related side effects like palpitations or a fast heart rate?

A: Cardiovascular adverse effects, specifically palpitations and tachycardia (a fast or irregular heartbeat), are listed in the official adverse reaction reports.

Q: Is Spasmorest commonly associated with mental side effects like confusion or agitation?

A: Mental and mood changes are reported side effects, especially in older or sensitive individuals. These effects include confusion, agitation, nervousness, hallucinations, and unusual excitement.

Q: Does Spasmorest lose effectiveness if taken with food?

A: Administration guidelines recommend that the medicine be taken 30 to 60 minutes before a meal.

Q: Is Spasmorest available over the counter (OTC) in any countries or regions?

A: Regulatory sources confirm that the active ingredient, Dicyclomine, is legally classified as a prescription-only medicine in several countries, including the United States, Canada, and the United Kingdom.

Q: Does Spasmorest interact with cannabis or CBD products?

A: Regulatory-aligned patient information notes that cannabis (marijuana) may increase side effects such as drowsiness and dizziness when combined with this medication.

How to Store and Dispose of Spasmorest

The required storage conditions for Spasmorest (Dicyclomine/Mebeverine) are defined by official regulatory labeling to ensure product stability.

Required Storage and Protection

Requirement Type	Official Labeled Condition
Temperature	Store at 20 °C to 25 °C (Controlled Room Temperature) or not greater than 30 °C.
Protection	Product must be protected from light, moisture, and excessive heat.
Packaging	Store in the original container or a tight container; keep out of the sight and reach of children.

Disposal Instructions

Official disposal guidelines mandate that unused or expired medication should not be flushed down the toilet. The required method is to utilize an authorized drug take-back program. If a program is unavailable, the medication should be secured in a sealed bag with an undesirable substance (e.g., kitty litter) and placed in the household trash.